India's DMPLOI - Jobs & Networking App
The Nifty Pharma index closed lower on Friday at 22,175.40 (-0.55%), weighed down by profit-booking in large-cap counters. While Divi’s Labs, Aurobindo Pharma, and Lupin supported the market with steady gains, heavyweights like Cipla and Sun Pharma dragged the index into the red.
Broader sentiment across Dalal Street remained cautious. With geopolitical tension rising between India and the US, market participants are treading carefully. Concerns around diplomatic friction, trade policies, and foreign fund flows are keeping risk appetite subdued.
Investors are now looking ahead to 3rd November, expecting clarity from global cues, macro announcements, and institutional flows. Analysts suggest market direction in the coming week may depend heavily on global political developments and commentary from US policymakers.
Despite short-term volatility, the pharmaceutical sector continues to hold a long-term bullish outlook backed by robust earnings momentum, strong domestic demand, and healthy export pipelines. Dips may continue to attract accumulation in fundamentally strong pharma names.
